Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-95251 (Anzurstobart) alone and in combination in advanced cancers
NCT03783403Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2019
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of anzurstobart in solid tumor (advanced stage), colorectal cancer (CRC), squamous cell carcinoma of the head and neck (HNSCC) and 3 more (3 arms), sponsored by Celgene Corporation. Primary endpoints: Non-Tolerated Dose at 18 months, Maximum Tolerated Dose at 18 months and 1 more. Started Mar 2019; status: terminated.
02
Drugs
anzurstobart
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)squamous cell carcinoma of the head and neck (HNSCC)non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03783403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783403.